

IN THE CLAIMS

Original Claims 1-66 were previously canceled.

Claims 67-136 are pending in this Application.


Claims 67-104 and 113-120 are currently amended.

Claims 105-112 and 121-122 are canceled.

Claims 123-136 were previously presented.

Claims 137-154 are new.

67. (currently amended) A compound for modulating tyrosine kinase activity of Formula I,



or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof, wherein,

R¹ is C₁-C₃ alkyl optionally substituted with between one and three R⁵⁰ substituents;

R² is selected from halogen, trihalomethyl, -CN, -NH₂, -NO₂, -OR³, -N(R³)R⁴,

-S(O)₀₋₂R⁴, -SO₂N(R³)R⁴, -CO₂R³, -C(=O)N(R³)R⁴, -N(R³)SO₂R⁴, -N(R³)C(=O)R³,

-N(R³)CO₂R⁴, -C(=O)R³, ~~optionally substituted lower alkyl, optionally substituted lower alkenyl, and optionally substituted lower alkynyl;~~

R³ is -H or R⁴;

R⁴ is selected from ~~optionally substituted lower alkyl; lower alkyl substituted with one, two, or three halogen; optionally substituted aryl; aryl substituted with one, two, or three halogen; optionally substituted unsubstituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl~~ lower alkyl substituted with one, two, or three halogen; optionally substituted aryl; aryl substituted with one, two, or three halogen; optionally substituted unsubstituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl ~~optionally substituted with one alkyl; or~~

R^3 and R^4 , when taken together with a common nitrogen to which they are attached, form ~~an optionally substituted~~ a five- to seven-membered heterocycl~~y~~l, ~~said optionally substituted~~ ~~five- to seven-membered heterocycl~~y~~l~~ optionally containing at least one additional heteroatom selected from N, O, S, and P where the five- to seven-membered heterocyclyl is optionally substituted by one, two, or three alkyl;

q is 0, 1, 2, 3, 4, or 5;

Z is selected from -OCH₂-, -O-, -S(O)₀₋₂-, -N(R⁵)CH₂-, and -NR⁵-;

R^5 is -H or ~~optionally substituted~~ lower alkyl;


R^{50} is -H, halo, trihalomethyl, -OR³, -N(R³)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R³)R⁴, -CO₂R³, -C(=O)N(R³)R⁴, -C(=NR²⁵)N(R³)R⁴, -C(=NR²⁵)R⁴, -N(R³)SO₂R⁴, -N(R³)C(O)R³, -NCO₂R³, -C(=O)R³, ~~optionally substituted~~ alkoxy, ~~optionally substituted~~ lower alkyl, ~~optionally substituted~~ aryl, ~~optionally substituted~~ unsubstituted lower arylalkyl, ~~optionally substituted~~ heterocycl~~y~~l, and ~~optionally substituted~~ lower heterocycl~~y~~lalkyl optionally substituted with one alkyl; or

two of R^{50} , when taken together on the same carbon are oxo; or

two of R^{50} , when taken together with a common carbon to which they are attached, form a ~~optionally substituted~~ three- to seven-membered spirocycl~~y~~l, ~~said optionally substituted~~ ~~three- to seven-membered spirocycl~~y~~l~~ optionally containing at least one additional heteroatom selected from N, O, S, and P;

R^{25} is selected from -H, -CN, -NO₂, -OR³, -S(O)₀₋₂R⁴, -CO₂R³, ~~optionally substituted~~ lower alkyl, ~~optionally substituted~~ lower alkenyl, and ~~optionally substituted~~ lower alkynyl;

$M^1-M^2-M^3-M^4$ - together are according to formula II:



II

wherein X^1 , X^2 , and optionally X^3 , represent the atoms of a saturated bridged ring system, said saturated bridged ring system containing up to three annular heteroatoms represented by any of X^1 , X^2 , and X^3 ; wherein,

each X^1 is independently selected from $-C(R^6)R^7-$, $-O-$, $-S(O)_{0-2}-$, and $-NR^8-$;
each X^2 is independently a bridgehead methine optionally substituted with R^6 , or
a bridgehead nitrogen;
each X^3 is independently selected from $-C(R^6)R^7-$, $-O-$, $-S(O)_{0-2}-$, and $-NR^8-$;
provided, for X^1 , X^2 , and X^3 , there are no nitrogen-nitrogen annular bonds nor
geminal di-nitrogen substitutions;

E is selected from $-NR^9-$, $-O-$, and absent;

Y is either:

a C_{1-3} alkylene linker, between the oxygen at the 7-position of the quinazoline ring system of I and either E, or when E is absent, any ring atom of the saturated bridged ring system except X^2 , when X^2 is a bridgehead nitrogen; provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of I and either E, or when E is absent, any heteroatom represented by X^1 , X^2 or X^3 ; or

Y is absent, when Y is absent, E is also absent; said saturated bridged ring system is directly attached to the oxygen at the 7-position of the quinazoline ring system of I via a carbon atom of said saturated bridged ring system;

m and p are each independently ~~from one to four~~ 1, 2, 3, or 4;

n is ~~from zero to two~~ 0, 1, or 2, when n is zero, then there is a direct single bond between the two bridgehead X^2 's;

R^6 and R^7 are each independently selected from -H, halogen, trihalomethyl, $-CN$, $-NH_2$, $-NO_2$, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(O)R^3$, $-NCO_2R^3$, $-C(O)R^3$, ~~optionally substituted lower alkyl, optionally substituted aryl, optionally substituted unsubstituted lower arylalkyl, optionally substituted heterocyclyl, optionally substituted lower heterocyclalkyl optionally substituted with one alkyl~~; or

R⁶ and R⁷, when taken together are oxo; or

R⁶ and R⁷, when taken together with a common carbon to which they are attached, form a ~~optionally substituted three- to seven-membered spirocyclyl, said optionally substituted three to seven membered spirocyclyl~~ optionally containing at least one additional heteroatom selected from N, O, S, and P; and

R⁸ is selected from R³, -SO₂N(R³)R⁴, -CO₂R³, -C(O)N(R³)R⁴, -SO₂R⁴, and -C(O)R³;

R⁹ is -H or ~~optionally substituted lower alkyl~~;

with the proviso that when Y is a C₁₋₃ alkylene linker, E is absent, Z is -NH- or -N(CH₃)-, R¹ is a C₁₋₃ alkyl, R² is -H or halogen, n = 0, and the atoms X¹ of one bridge of the saturated bridged ring system, when combined with both bridgehead atoms, X², of the saturated bridged ring system, represent:

either a pyrrolidine ring or a piperidine ring, and any atom, X¹ or X², of either of said pyrrolidine ring or said piperidine ring is attached to Y; then the other bridge of said saturated bridged ring system cannot be any one of -OC(O)CH₂-, -CH₂OC(O)-, -OC(O)CH₂CH₂-, -CH₂OC(O)CH₂-, -CH₂CH₂OC(O)-, -OC(O)CH₂NH-, -OC(O)CH₂N(C₁₋₄alkyl)-, and -OC(O)CH₂O-;[[or]] and

either a piperazine ring or a 4-(C₁₋₄ alkyl)-piperazine ring, and any atom, X¹ or X², of either of said piperazine ring or said 4-(C₁₋₄ alkyl)-piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 2- and the 3-position of either of said piperazine ring or said 4-(C₁₋₄ alkyl)-piperazine ring, cannot be one of -CH₂OC(O)CH₂-, -CH₂CH₂OC(O)-, and either of the two aforementioned bridges cannot be optionally substituted by one or two C₁₋₂alkyl groups;[[or]] and

a piperazine ring, and any atom, X¹ or X², of said piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 3- and the 4-position of said piperazine ring, cannot

be one of -C(O)OCH₂CH₂- or -CH₂OC(O)CH₂- (and only when either of -C(O)OCH₂CH₂- or -CH₂OC(O)CH₂- is attached to the 3-position of said piperazine ring via their left-hand end as depicted above), and either of the two aforementioned bridges cannot be optionally substituted by one or two C₁₋₂ alkyl groups, and ;[[or]] and

a 2-oxomorpholine ring, said 2-oxomorpholine ring attached to Y via its 4-position; then the other bridge of said saturated bridged ring system, only when attached via the 5- and the 6-position of said 2-oxomorpholine ring, cannot be one of -(CH₂)_g-, -CH₂WCH₂-, -CH₂WCH₂CH₂-, and -CH₂CH₂WCH₂-, wherein W is -O-, -S(O)₀₋₂-, -NH-, or -N(C₁₋₄ alkyl)- and wherein g is 2, 3, or 4.

68. (currently amended) The compound according to claim 67, wherein Z is -NR⁵-; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

69. (currently amended) The compound according to claim 68, wherein R² is selected from halogen, trihalomethyl, -CN, -NO₂, -OR³, and optionally substituted lower alkyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

70. (currently amended) The compound according to claim 69, wherein R¹ is an unsubstituted C₁₋₃ alkyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

71. (currently amended) The compound according to claim 70, wherein the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], [3.1.0], [3.3.3], [3.3.2], [3.3.1], [3.2.2], [3.2.1], [2.2.2], and [2.2.1]; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

72. (currently amended) The compound according to claim 71, wherein Y is selected from -CH₂CH₂-,-CH₂-, and absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

73. (currently amended) The compound according to claim 72, wherein q is 1, 2, or 3; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

74. (currently amended) The compound according to claim 73, wherein R⁵ is -H; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.


75. (currently amended) The compound according to claim 74, wherein R¹ is methyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

76. (currently amended) The compound according to claim 75, wherein the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], and [3.1.0]; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

77. (currently amended) The compound according to claim 76, wherein said saturated bridged ring system contains one or two annular nitrogens, said one or two annular nitrogens are selected from -NR⁸-, when X¹, and a bridgehead nitrogen, when X²; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

78. (currently amended) The compound according to claim 77, wherein E is absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

79. (currently amended) The compound according to claim 78, wherein said saturated bridged ring system is according to formula III;




III

wherein A is selected from -O-, -S(O)₀₋₂₋, -NR⁸-, and absent; and e is 0 or 1; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

80. (currently amended) The compound according to claim 79, wherein Y is -CH₂-; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

81. (currently amended) The compound according to claim 80, wherein A is selected from -NR⁸-, wherein R⁸ is selected from -H, ~~optionally substituted~~ lower alkyl, -CO₂R³, -C(O)N(R³)R⁴, -SO₂R⁴, and -C(O)R³; -O-; and absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

82. (currently amended) The compound according to claim 81, wherein




R^{2a}, R^{2b}, and R^{2c} are each independently selected from F, Cl, and Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

83. (currently amended) The compound according to claim 82, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single geometric isomer, stereoisomer, racemate,

enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

84. (currently amended) The compound according to claim 77, wherein said saturated bridged ring system is according to either formula V or formula VI;



V




VI


wherein R⁸ is selected from -H, optionally substituted lower alkyl, -CO₂R³, -C(O)N(R³)R⁴, -SO₂R⁴, and -C(O)R³; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

85. (currently amended) The compound according to claim 84, wherein Y is either -CH₂- or absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

86. (currently amended) The compound according to claim 85, wherein



of I is selected from:




and, wherein R^{2a}, R^{2b}, and R^{2c} are each independently selected from F, Cl, and Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

87. (currently amended) The compound according to claim 86, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

88. (currently amended) The compound according to claim 87, wherein R⁸ is methyl or ethyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

89. (currently amended) The compound according to claim 78, wherein said



saturated bridged ring system is according to formula VII;

VII

wherein A is selected from -O-, -S(O)₀₋₂-, -NR⁸-, -CR⁶R⁷-, and absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

90. (currently amended) The compound according to claim 89, wherein R³ is selected from -H and optionally substituted alkyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.


91. (currently amended) The compound according to claim 90 wherein A is either -C(R⁶)R⁷- or absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

92. (currently amended) The compound according to claim 91, wherein A is either -CH₂- or absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

93. (currently amended) The compound according to claim 92, wherein Y is -CH₂-; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

94. (currently amended) The compound according to claim 93, wherein q is 3; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

95. (currently amended) The compound according to claim 94, wherein




R^{2a}, R^{2b}, and R^{2c} are each independently selected from F, Cl, and Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

96. (currently amended) The compound according to claim 95, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.


97. (currently amended) The compound according to claim 75, wherein the saturated bridged ring system has a geometry selected from the group consisting of [3.3.1], [3.2.1], and [2.2.1]; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

98. (currently amended) The compound according to claim 97, wherein said saturated bridged ring system contains one or two annular nitrogens, said one or two annular nitrogens are selected from -NR⁸-, when X¹, and a bridgehead nitrogen, when X²; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

99. (currently amended) The compound according to claim 98, wherein said saturated bridged ring system is according to formula **VIII** or formula **IX**;



VIII




IX

wherein R⁸ is selected from -H, optionally substituted lower alkyl, -CO₂R³, -C(O)N(R³)R⁴, -SO₂R⁴, and -C(O)R³; and R²⁶ is C₁₋₃ alkyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

100. (currently amended) The compound according to claim 99, wherein Y is -CH₂CH₂-; and E is either absent or -N(R⁹)-; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

101. (currently amended) The compound according to claim 100, wherein q is 3; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

102. (currently amended) The compound according to claim 101, wherein




103. (currently amended) The compound according to claim 102, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single geometric isomer, stereoisomer, racemate,

enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

104. (currently amended) The compound according to claim 103, wherein R⁸ is methyl or ethyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

Claims 105-112 (canceled)

113. (currently amended) A compound for modulating tyrosine kinase activity of Formula Ia,



Ia

or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof, wherein, q is 1, 2, or 3;

R² is selected from halogen, trihalomethyl, -CN, -NO₂, -OR³, optionally substituted lower alkyl, and piperazinyl substituted with methyl;

Y is selected from -CH₂CH₂-, -CH₂-, and absent;

Y is either:

-CH₂- or -CH₂CH₂- provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of Ia and E when E is -NR⁹- or -O-; or

Y is absent; and when Y is absent, E is also absent;

E is selected from -NR⁹-, -O-, and absent;

R³ is -H or R⁴;

R⁴ is selected from optionally substituted lower alkyl; lower alkyl substituted with one, two, or three halogen; optionally substituted aryl; aryl substituted with one, two,

or three halogen; optionally substituted unsubstituted lower arylalkyl; optionally substituted heterocyclyl; and optionally substituted lower heterocyclylalkyl optionally substituted with one alkyl; or

R³ and R⁴, when taken together with a common nitrogen to which they are attached, form an optionally substituted a five- to seven-membered heterocyclyl, said optionally substituted five to seven membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P where the five- to seven-membered heterocyclyl is optionally substituted by one, two, or three alkyl;

R⁹ is -H or optionally substituted lower alkyl;

R¹⁰ is selected from -H, optionally substituted alkyl, and -OR¹³; and R¹¹ and R¹² are each independently selected from -H, -CF₃, -F, -N(R³)R⁴, -N(C=O)R³, -N(R³)SO₂R³, -S(O)₀₋₂R¹³, -OR¹³, -OS(O)₀₋₂R^{13a}, -OS(O)₂alkyl, -NH₂, and alkyl substituted with alkoxy; or

R¹⁰ is selected from -H, and -OR¹³; and R¹¹ and R¹², when taken together, are oxo, exo-alkenyl, or when taken together with the carbon to which they are attached, form a three- to seven-membered spirocyclyl which three to seven membered spirocyclyl is optionally substituted with alkyl and which optionally contains one or two oxygen atoms; and

R¹³ is selected from -H, -C(=O)R⁴, optionally substituted lower alkynyl, optionally substituted unsubstituted lower arylalkynyl, optionally substituted lower heterocyclalkynyl, optionally substituted lower alkenyl, optionally substituted unsubstituted lower arylalkenyl, optionally substituted lower heterocyclalkenyl optionally substituted with one alkyl, optionally substituted lower alkyl, lower alkyl substituted with one, two, or three halogen, optionally substituted unsubstituted lower arylalkyl, optionally substituted aryl, optionally substituted lower heterocyclalkyl optionally substituted with one alkyl, and optionally substituted heterocyclyl; or

two R¹³'s, when taken together, form 1) a corresponding spirocyclic ketal from R¹¹, R¹² and the carbon to which they are attached, when R¹¹ and R¹² are both -OR¹³, or 2) a corresponding cyclic ketal from R¹⁰ and one of R¹¹ and R¹², and the

corresponding carbons to which they are attached, when R¹⁰ is -OR¹³, and at least one of R¹¹ and R¹² is also -OR¹³, and which spirocyclic and cyclic ketal is-are independently optionally substituted with one or two alkyl; and
R^{13a} is alkyl.

114. (currently amended) The Compound of Claim 113 wherein

q is 1, 2, or 3;

R² is selected from halogen, trihalomethyl, -CN, -NO₂, -OR³, and optionally substituted lower alkyl;

~~Y is selected from CH₂CH₂, CH₂, and absent;~~

Y is either:

-CH₂- or -CH₂CH₂- provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of Ia and E when E is -NR⁹- or -O-; or

Y is absent; and when Y is absent, E is also absent;

E is selected from -NR⁹-, -O-, and absent;

R³ is -H or R⁴;

R⁴ is selected from optionally substituted lower alkyl, lower alkyl substituted with one, two, or three halogen, optionally substituted aryl, aryl substituted with one, two, or three halogen, optionally substituted unsubstituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl optionally substituted with one alkyl; or

R³ and R⁴, when taken together with a common nitrogen to which they are attached, form an optionally substituted a five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P where the five- to seven-membered heterocyclyl is optionally substituted by one, two, or three alkyl;

R⁹ is -H or optionally substituted lower alkyl;

R¹⁰ is selected from -H, optionally substituted alkyl, and -OR¹³; and R¹¹ and R¹² are each independently selected from -H, -CF₃, -F, -N(R³)R⁴, -N(C=O)R³, -N(R³)SO₂R³, -S(O)₀₋₂R¹³, and -OR¹³; or

R¹⁰ is selected from -H, and -OR¹³; and R¹¹ and R¹², when taken together, are oxo, exo-alkenyl, or when taken together with the carbon to which they are attached, form a three- to seven-membered spirocyclyl; and

R¹³ is selected from -H, -C(=O)R⁴, ~~optionally substituted lower alkynyl, optionally substituted—unsubstituted lower arylalkynyl, optionally substituted—lower heterocyclalkynyl optionally substituted with one alkyl, optionally substituted lower alkenyl, optionally substituted unsubstituted lower arylalkenyl, optionally substituted—lower heterocyclalkenyl optionally substituted with one alkyl, optionally substituted—lower alkyl, lower alkyl substituted with one, two, or three halogen, optionally substituted unsubstituted lower arylalkyl, optionally substituted—aryl, optionally substituted—lower heterocyclalkyl optionally substituted with one alkyl, and optionally substituted heterocyclyl; or~~ two R¹³'s, when taken together, form 1) a corresponding spirocyclic ketal from R¹¹, R¹² and the carbon to which they are attached, when R¹¹ and R¹² are both -OR¹³, or 2) a corresponding cyclic ketal from R¹⁰ and one of R¹¹ and R¹², and the corresponding carbons to which they are attached, when R¹⁰ is -OR¹³, and at least one of R¹¹ and R¹² is also -OR¹³; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

115. (currently amended) The compound according to claim 114, wherein Y is either -CH₂- or absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

116. (currently amended) The compound according to claim 115, wherein one of R¹¹ and R¹² is -OR¹³, wherein R¹³ is selected from -H, -C(O)R⁴, ~~and optionally substituted lower alkyl, and lower alkyl substituted with one, two, or three halogen;~~ and R¹⁰ and the other of R¹¹ and R¹² are both -H; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

117. (currently amended) The compound according to claim 115, wherein one of R¹¹ and R¹² is -F; and R¹⁰ and the other of R¹¹ and R¹² are both -H; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

118. (currently amended) The compound according to claim 115, wherein R¹³ is an alkyl group containing at least one fluorine substitution thereon; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

119. (currently amended) The compound according to claim 115, wherein q is 2 or 3; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

120. (currently amended) The compound according to claim 119, wherein each R² is independently selected from -F, -Cl, -Br, -CF₃, -CH₃, and -OR²⁵; wherein R²⁵ is either methyl or aryl, each optionally substituted with one to three halogens; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof. Claims 121-122 (canceled)

123. (previously presented) A compound selected from 1,4:3,6-dianhydro-2-O-[4-(methyloxy)carbonyl-2-(methyloxy)phenyl]-5-O-(methylsulfonyl)-D-glucitol; 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{2-(methyloxy)-4-[(methyloxy)carbonyl]phenyl}-L-iditol; 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{2-(methyloxy)-4-[(methyloxy)carbonyl]-5-nitrophenyl}-L-iditol; 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{5-amino-2-(methyloxy)-4-[(methyloxy)carbonyl]-phenyl}-L-iditol; 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-oxo-3,4-dihydroquinazolin-7-yl]-L-iditol; and 1,4:3,6-dianhydro-5-O-[4-chloro-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-L-iditol; and a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

124. **(previously presented)** A compound selected from 1,1-dimethylethyl (3a*R*,6a*S*)-5-(hydroxymethyl)hexahydro cyclopenta[c] pyrrole-2(1*H*)-carboxylate; 1,1-dimethylethyl (3a*R*,6a*S*)-5-{{[(methylsulfonyl)oxy]methyl}hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate; (3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl methanesulfonate; (3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl acetate; (3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl acetate; hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl acetate; (3*S*,9a*S*)-3-(chloromethyl)hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazine; (3*R*,9a*S*)-3-(chloromethyl)hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazine; 3-(chloromethyl)hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazine; [(3*S*,8a*S*)-2-methyl-1-oxooctahydropyrrolo[1,2-*a*]pyrazin-3-yl]methyl methanesulfonate; (3*S*,8a*S*)-3-(hydroxymethyl)-2-methylhexahydropyrrolo[1,2-*a*]pyrazin-1(2*H*)-one; (3*S*,8a*S*)-3-(hydroxymethyl)-hexahydropyrrolo[1,2-*a*]pyrazin-1(2*H*)-one; (3*S*,8a*S*)-3-{{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl}-2-methylhexahydropyrrolo[1,2-*a*]pyrazin-1(2*H*)-one; (3*S*,8a*S*)-3-{{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl}hexahydropyrrolo[1,2-*a*]pyrazin-1(2*H*)-one; (3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl methanesulfonate; (3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethanol; (3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl acetate; (3*S*,8a*R*)-3-(chloromethyl)hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine; (3*R*,8a*S*)-3-(chloromethyl)hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine; (3*R*,8a*R*)-3-(chloromethyl)hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine; and (3*S*,8a*S*)-3-(chloromethyl)hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine; and a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

125. **(previously presented)** A pharmaceutical composition comprising a compound of Formula I or Ia and a pharmaceutically acceptable carrier.

126. **(previously presented)** A method of modulating the *in vivo* activity of a kinase selected from ephrin and EGFR, the method comprising administering to a subject an

effective amount of a compound of Formula I or Ia optionally together with a pharmaceutically acceptable carrier.

127. **(previously presented)** A method of treating a disease or a disorder associated with abnormal cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound of Formula I or Ia optionally together with a pharmaceutically acceptable carrier.

128. **(previously presented)** The method of Claim 127 where the disease is cancer.

129. **(previously presented)** The method of Claim 128 where the cancer is modulated by one or more kinases selected from ephrin, KDR, Flt-1, EGFR, and ErbB2.

130. **(previously presented)** The method of Claim 127 where the cancer is selected from non-small cell lung cancer, glioblastoma, pancreatic cancer, cancer of the nervous system, cancer of the large bowel, multiple myeloma, undifferentiated small cell bronchogenic carcinoma, gastrointestinal cancer, esophageal cancer, malignant melanoma, neuroblastoma, osteosarcoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, urethral cancer, and prostate cancer.

131. **(previously presented)** The method of Claim 127 where the cancer is selected from non-small cell lung cancer, glioblastoma, pancreatic cancer, cancer of the nervous system, cancer of the large bowel, neuroblastoma, and gastrointestinal cancer.

132. **(previously presented)** The method of Claim 127 where the cancer is selected from ovarian cancer, cervical cancer, bladder cancer, esophageal cancer, and malignant melanoma, and prostate cancer.

133. **(previously presented)** The method of Claim 128 where the cancer is non-small cell lung cancer.

134. **(previously presented)** The method of Claim 128 where the cancer is glioblastoma.

135. **(previously presented)** The method of Claim 130 where the gastrointestinal cancer is stomach cancer.

136. (previously presented) The method of Claim 127 where the disease is selected from ischemic coronary artery disease, diabetic retinopathy, psoriasis and rheumatoid arthritis.

137. (new) The compound of Claim 68 selected from

<i>N</i> -(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(8 <i>aR</i>)-tetrahydro-1 <i>H</i> -[1,3]thiazolo[4,3- <i>c</i>][1,4]oxazin-6-ylmethyl]oxy}quinazolin-4-amine;
3,6-anhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-1,2- <i>O</i> -(1-methylethylidene)-beta-L-xylo-hexofuranose;
3,6-anhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-1,2- <i>O</i> -(1-methylethylidene)-β-D-idofuranose;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-[(octahydro-2 <i>H</i> -quinolizin-3-ylmethyl)oxy]quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chlorophenyl)-7-{[(3 <i>a'S</i> ,4 <i>R</i> ,6 <i>S</i> ,6 <i>a'R</i>)-2,2-dimethyltetrahydrospiro[1,3-dioxolane-4,3'-furo[3,2- <i>b</i>]furan]-6'-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
1,4:3,6-dianhydro-2- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5- <i>O</i> -(methylsulfonyl)-L-glucitol;
1,4:3,6-dianhydro-2- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5- <i>O</i> -(methylsulfonyl)-D-glucitol;
2-amino-1,4:3,6-dianhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-D-iditol;
2-amino-1,4:3,6-dianhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-L-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5- <i>O</i> -(6-(methyloxy)-4-[(4-(4-methylpiperazin-1-yl)phenyl]amino)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5- <i>O</i> -(6-(methyloxy)-4-[(4-(4-methylpiperazin-1-yl)phenyl]amino)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5- <i>O</i> -[4-[(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5- <i>O</i> -[4-[(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-2-deoxy-5- <i>O</i> -[4-[(2,3-dichloro-4-(4-methylpiperazin-1-yl)phenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;

1,4:3,6-dianhydro-2-deoxy-5-O-[4-{[2,3-dichloro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-L-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-{[3,4-dichloro-2-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-{[3,4-dichloro-2-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-L-iditol; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

138. (new) The Compound of Claim 81 selected from

N-(4-bromo-2,3-dichlorophenyl)-7-{{(3*R*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{{(3*R*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{{(3*R*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{{(3*R*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{{(3*S*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{{(3*S*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{{(3*S*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-[(hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy]-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{{(3*S*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-{{(3*S*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{{(3*S*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichloro-2-fluorophenyl)-7-{[(3*R*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3*R*,9*aS*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine; and

a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

139. (new) The Compound of Claim 81 selected from

N-(3,4-dichlorophenyl)-7-{[(3*R*,8*aR*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3*S*,8*aS*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-{[(3*S*,8*aR*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-{[(3*S*,8*aS*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-{[(3*R*,8*aS*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichloro-2-fluorophenyl)-7-{[(3*S*,8*aS*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3*S*,8*aS*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3-chloro-2,4-difluorophenyl)-7-{[(3*S*,8*aS*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-2,3-dichlorophenyl)-7-{[(3*S*,8*aS*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(4,5-dichloro-2-fluorophenyl)-7-{[(3*S*,8*aS*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine; and

a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

140. (new) The Compound of Claim 85 selected from

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3*aR*,6*aS*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

<p><i>N</i>-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p>7-({[(3a<i>R</i>,6a<i>S</i>)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-<i>N</i>-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3a<i>R</i>,6a<i>S</i>)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;</p>
<p><i>N</i>-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;</p>
<p><i>N</i>-(3,4-dichloro-2-fluorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-ethyoctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;</p>
<p><i>N</i>-(3,4-dichloro-2-fluorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(3-chloro-2,4-difluorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(4,5-dichloro-2-fluorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(4-bromo-2,3-dichlorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(3,4-dichlorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-ethyoctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;</p>
<p><i>N</i>-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a<i>R</i>,6a<i>S</i>)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine; and</p>

a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

141. (new) The Compound of Claim 85 selected from

N-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,5*S*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3a*R*,5*S*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3a*R*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3a*R*,5*S*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3a*R*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{{[(3a*R*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]oxy}-6-(methyloxy)quinazolin-4-amine; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

142. (new) The Compound of Claim 87 selected from

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6*aS*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5*r*,6*aS*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3a*R*,5*r*,6*aS*)-2-acetyl octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-*N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{{[(3a*R*,5*r*,6*aS*)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3a*R*,6*aS*)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate;

ethyl (3a <i>R</i> ,5 <i>r</i> ,6a <i>S</i>)-5-[(4-[4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy)methyl]hexahydrocyclopenta[c]pyrrole-2(1 <i>H</i>)-carboxylate;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6a <i>S</i>)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6a <i>S</i>)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6a <i>S</i>)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>s</i> ,6a <i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6a <i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>s</i> ,6a <i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4,5-dichloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>s</i> ,6a <i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4,5-dichloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6a <i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>s</i> ,6a <i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6a <i>S</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6a <i>S</i>)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6a <i>S</i>)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
1,1-dimethylethyl (3a <i>R</i> ,6a <i>S</i>)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1 <i>H</i>)-carboxylate;

N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{{[(3a*R*,5*r*,6*aS*)-octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}quinazolin-4-amine;
1,1-dimethylethyl (3*aR*,6*aS*)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1*H*)-carboxylate; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

143. (new) The Compound of Claim 85 selected from

N-(3,4-dichloro-2-fluorophenyl)-7-{{[(3*aR*,5*r*,6*aS*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{{[(3*aR*,5*r*,6*aS*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}-6-(methyloxy)quinazolin-4-amine;
7-{{[(3*aR*,5*r*,6*aS*)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}-*N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{{[(3*aR*,5*r*,6*aS*)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3*aR*,5*r*,6*aS*)-5-{{(4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl)oxy}methyl}hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{{[(3*aR*,5*r*,6*aS*)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{{[(3*aR*,5*r*,6*aS*)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{{[(3*aR*,5*r*,6*aS*)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{{[(3*aR*,5*s*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{{[(3*aR*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{{[(3*aR*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{{[(3*aR*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}-6-(methyloxy)quinazolin-4-amine;

<i>N</i> -(4,5-dichloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-2,3-dichlorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(3,4-dichlorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
<i>N</i> -(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a <i>R</i> ,5 <i>r</i> ,6 <i>aS</i>)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine; and
1,1-dimethylethyl (3 <i>aR</i> ,6 <i>aS</i>)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1 <i>H</i>)-carboxylate;
<i>N</i> -(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3 <i>aR</i> ,5 <i>r</i> ,6 <i>aS</i>)-octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}quinazolin-4-amine
1,1-dimethylethyl (3 <i>aR</i> ,6 <i>aS</i>)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1 <i>H</i>)-carboxylate; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

144. (new) The Compound of Claim 143 selected from *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3*aR*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3*aR*,5*r*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; and *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3*aR*,5*s*,6*aS*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; and optionally as a pharmaceutically acceptable salt or hydrate thereof.

145. (new) The pharmaceutical composition of Claim 144.
146. (new) The Compound of Claim 143 selected from 1,1-dimethylethyl (3aR,6aS)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate; N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine; N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy}quinazolin-4-amine; 1,1-dimethylethyl (3aR,6aS)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1H)-carboxylate; and a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.
147. (new) The Compound of Claim 144 named *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt or hydrate thereof.
148. (new) The pharmaceutical composition of Claim 147.
149. (new) The Compound of Claim 96 selected from
- | |
|--|
| (3 <i>S</i> ,9 <i>aS</i>)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2 <i>H</i> -pyrido[1,2-a]pyrazin-1(6 <i>H</i>)-one; |
| (3 <i>S</i> ,9 <i>aR</i>)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2 <i>H</i> -pyrido[1,2-a]pyrazin-1(6 <i>H</i>)-one; |
| (3 <i>S</i> ,8 <i>aS</i>)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2 <i>H</i>)-one; |
| (3 <i>S</i> ,8 <i>aR</i>)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2 <i>H</i>)-one; |
| (3 <i>S</i> ,8 <i>aS</i>)-3-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2 <i>H</i>)-one; |
| (3 <i>S</i> ,8 <i>aS</i>)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-methylhexahydropyrrolo[1,2-a]pyrazin-1(2 <i>H</i>)-one; and |

a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

150. (new) The Compound of Claim 99 selected from

N-(3,4-dichlorophenyl)-7-({2-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-[(2-{[(3-*endo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}ethyl)oxy]-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-{[2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-({2-[(3-*endo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-{[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-({[(3-*endo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-{[8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichlorophenyl)-7-{[(3-*exo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-6-(methyloxy)quinazolin-4-amine;

7-{[(3-*endo*)-8-azabicyclo[3.2.1]oct-3-ylmethyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine;

1,1-dimethylethyl (3-*endo*)-3-(2-{[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}ethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate; and

7-({2-[(3-*endo*)-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy) quinazolin-4-amine; and

a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

151. (new) The Compound of Claim 117 selected from

1,4:3,6-dianhydro-5-*O*-[4-[(2-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;

1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-[(2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-[(4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(2-bromophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(3-bromophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

152. (new) The Compound of Claim 120 selected from

1,4:3,6-dianhydro-5-({[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-2-deoxy-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-O-methyl-D-threo-hexitol;

1,4:3,6-dianhydro-5-deoxy-5-({[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-methyl-5-O-{6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl}-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-sorbose ethylene glycol acetal;
1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-(difluoromethyl)-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-ethyl-L-iditol;

1,4:3,6-dianhydro-2-O-[4-[(3-bromo-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-D-xylo-hexitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-D-glucitol;
methyl 3,6-anhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-alpha-L-idofuranoside;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-5-methylidene-D-xylo-hexitol;
methyl 3,6-anhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-beta-L-idofuranoside;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{6-(methyloxy)-4-[(2,3,4-trifluorophenyl)amino]}quinazolin-7-yl}-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(2-chloro-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(2-bromo-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,6-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{[4-fluoro-3-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,5-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,3-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;

1,4:3,6-dianhydro-5-O-[4-[(5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,5-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(3-chloro-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-2-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-[(2,4,5-trifluorophenyl)amino]quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-[(2,4,6-trifluorophenyl)amino]quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-chlorophenyl)oxy]-3,5-difluorophenyl]amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chloro-5-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[6-(methyloxy)-4-[(3,4,5-trichlorophenyl)amino]quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;

1,4:3,6-dianhydro-5-O-[4-[(4-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(2,5-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(2-bromo-4,6-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-{{[4-chloro-3-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-{{[2-chloro-5-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{{[2-fluoro-3-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-O-[4-{{[2-bromo-5-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-{{[2-bromo-4-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-[4-{{[4-fluoro-2-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-O-[4-{{[3-bromo-5-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-{{[3-bromo-4-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(5-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;

1,4:3,6-dianhydro-2-deoxy-5-O-[4-[(3,5-dimethylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-{{[2,5-bis(methyloxy)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-{{[5-chloro-2,4-bis(methyloxy)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-{{[4-chloro-2,5-bis(methyloxy)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-O-{{4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}-2-deoxy-2-fluoro-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-5-C-[(methyloxy)methyl]-L-glucitol;
1,4:3,6-dianhydro-5-O-{{4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}-2-O-methyl-2-C-[(methyloxy)methyl]-D-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-S-methyl-5-thio-D-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-S-methyl-5-thio-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-morpholin-4-yl-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-morpholin-4-yl-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(4-methylpiperazin-1-yl)-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(4-methylpiperazin-1-yl)-L-iditol;

1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-pyrrolidin-1-yl-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-pyrrolidin-1-yl-L-iditol;
2-O-acetyl-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
2-O-acetyl-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-L-iditol;
2-(acetylamino)-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-D-iditol;
2-(acetylamino)-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-L-iditol;

1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-5-C-(trifluoromethyl)-L-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-5-C-(trifluoromethyl)-D-glucitol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-D-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-C-(trifluoromethyl)-D-glucitol;
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

153. (new) The compound of Claim 152 selected from

1,4:3,6-dianhydro-5-({[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-2-deoxy-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-O-methyl-D-threo-hexitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;

1,4:3,6-dianhydro-2-O-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-methyl-5-O-{6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl}-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-sorbose ethylene glycol acetal;
1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-(difluoromethyl)-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-ethyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3-bromo-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-D-xylo-hexitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-D-glucitol;

methyl 3,6-anhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-alpha-L-idofuranoside;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-5-methylidene-D-xylo-hexitol;
methyl 3,6-anhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-beta-L-idofuranoside;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-C-(trifluoromethyl)-D-glucitol;
1,4:3,6-dianhydro-5-O-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-O-methyl-D-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-O-methyl-D-glucitol;
1,4:3,6-dianhydro-5-O-{4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}-2-deoxy-2-fluoro-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-glucitol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-S-methyl-5-thio-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-morpholin-4-yl-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(4-methylpiperazin-1-yl)-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-pyrrolidin-1-yl-L-iditol;
2-O-acetyl-1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-2-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-L-iditol;
1,4:3,6-dianhydro-5-O-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-L-iditol;

1,4:3,6-dianhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-L-iditol;
1,4:3,6-dianhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-L-iditol;
2-(acetylamino)-1,4:3,6-dianhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-L-iditol;
1,4:3,6-dianhydro-2- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5- <i>O</i> -methyl-5-C-(trifluoromethyl)-D-glucitol;
1,4:3,6-dianhydro-5- <i>O</i> -[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-L-iditol; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

154. (new) The Compound of Claim 124 selected from 1,1-dimethylethyl (3a*R*,6a*S*)-5-(hydroxymethyl)hexahydro cyclopenta[c] pyrrole-2(1*H*)-carboxylate; 1,1-dimethylethyl (3a*R*,6a*S*)-5-{{[(methylsulfonyl)oxy]methyl}hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate; and a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof; and optionally as a pharmaceutically acceptable salt or hydrate thereof.